Our findings aim to shed light on the intricate interplay between COVID-19 susceptibility and the risk of HER2-positive breast cancer, offering valuable insights that could inform clinical practice, public health policies, and future research endeavors. This evidence concerns the gene ERBB2 and breast carcinoma.